Article
Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia.
NEJM evidence - 1 Sept 2026
Jacoby Meagan A, Spencer David H, Gao Feng, Uy Geoffrey L, Burton Tasha, Heath Sharon E, Du Feiyu, O'Laughlin Michelle, Fulton Robert S, Miller Christopher A, Duncavage Eric J, Schroeder Mark A, Ghobadi Armin, Pusic Iskra, Stockerl-Goldstein Keith E, Kahl Brad S, Cashen Amanda F, Christopher Matthew J, Singh Nathan, Vij Ravi, Crees Zachary D, Wartman Lukas D, Day Ryan B, Fehniger Todd A, Oetjen Karolyn A, Patel Dilan A, Kim Miriam Y, Slade Michael J, Ferraro Francesca, Walter Matthew J, Abboud Camille N, Abboud Ramzi, Link Daniel C, Al-Mansour Zeina A, Cogle Christopher R, Huselton Eric J, DiPersio John F, Westervelt Peter, Ley Timothy J
Abstract excerpt
BACKGROUND: Optimal consolidation therapy for patients with intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) is controversial. Retrospective studies have suggested that the clearance of leukemia-associated mutations (LAMs) in CR1 may predict lower relapse risk and better outcomes with high-dose cytarabine (HiDAC) consolidation. We tested this hypothesis prospectively. METHODS: We...
Topics
Join the communities discussing this publication.